Today's Breaking News
- Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
- Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
- Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye
Latest R&D and Business News
- Perosphere Receives FDA IND Clearance to Initiate Clinical Investigations of the Safety and Efficacy of PER977 to Reverse the Activity of Anticoagulation Therapies including Factor Xa- and IIa-Inhibitors
- Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Oncolytics Biotech Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial
- Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis in Two Pivotal Phase 3 Studies
- Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors
- iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza
- Protalex Reports Positive Interim Review of Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis by Independent Data Safety Monitoring Committee
- Intercell Announces Pediatric Approval of its Japanese Encephalitis Vaccine in the U.S.
- Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin
- Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013
- Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
- 4SC's partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in liver cancer (HCC) in Japan